Parallel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,893
| Closed | -$76.2K | – | 3935 |
|
|
2026
Q1 | $76.2K | Buy |
1,893
+201
| +12% | +$4.33K | ﹤0.01% | 1746 |
|
|
2025
Q4 | $42.5K | Sell |
1,692
-278
| -14% | -$6.52K | ﹤0.01% | 1922 |
|
|
2025
Q3 | $44.6K | Buy |
1,970
+46
| +2% | +$1.07K | ﹤0.01% | 1847 |
|
|
2025
Q2 | $33.3K | Buy |
1,924
+855
| +80% | +$15.8K | ﹤0.01% | 1940 |
|
|
2025
Q1 | $23.4K | Buy |
1,069
+332
| +45% | +$9.17K | ﹤0.01% | 2055 |
|
|
2024
Q4 | $23.5K | Sell |
737
-1,142
| -61% | -$34.3K | ﹤0.01% | 2069 |
|
|
2024
Q3 | $54.2K | Buy |
1,879
+250
| +15% | +$9.26K | ﹤0.01% | 1582 |
|
|
2024
Q2 | $62.5K | Buy |
1,629
+88
| +6% | +$3.98K | ﹤0.01% | 1405 |
|
|
2024
Q1 | $90.6K | Buy |
1,541
+44
| +3% | +$2.81K | ﹤0.01% | 1218 |
|
|
2023
Q4 | $89.6K | Buy |
1,497
+71
| +5% | +$3.6K | ﹤0.01% | 1158 |
|
|
2023
Q3 | $54.2K | Buy |
1,426
+470
| +49% | +$20.6K | ﹤0.01% | 1354 |
|
|
2023
Q2 | $87.1K | Buy |
956
+14
| +1% | +$1.21K | ﹤0.01% | 1138 |
|
|
2023
Q1 | $62.1K | Buy |
942
+868
| +1,173% | +$50.1K | ﹤0.01% | 1272 |
|
|
2022
Q4 | $3.83K | Sell |
74
-7
| -9% | -$371 | ﹤0.01% | 2440 |
|
|
2022
Q3 | $6K | Buy |
81
+7
| +9% | +$414 | ﹤0.01% | 2188 |
|
|
2022
Q2 | $3K | Sell |
74
-56
| -43% | -$2.55K | ﹤0.01% | 2415 |
|
|
2022
Q1 | $6K | Sell |
130
-2
| -2% | -$88 | ﹤0.01% | 2213 |
|
|
2021
Q4 | $6K | Buy |
132
+73
| +124% | +$2.87K | ﹤0.01% | 2299 |
|
|
2021
Q3 | $2K | Hold |
59
| – | – | ﹤0.01% | 2646 |
|
|
2021
Q2 | $4K | Hold |
59
| – | – | ﹤0.01% | 2343 |
|
|
2021
Q1 | $3K | Hold |
59
| – | – | ﹤0.01% | 2328 |
|
|
2020
Q4 | $3K | Sell |
59
-51
| -46% | -$2.16K | ﹤0.01% | 2169 |
|
|
2020
Q3 | $3K | Sell |
110
-45
| -29% | -$1.34K | ﹤0.01% | 2166 |
|
|
2020
Q2 | $5K | Buy |
+155
| New | +$4.98K | ﹤0.01% | 1935 |
|
Other funds holding APLS
Parallel Advisors's APLS Position: Q2 2026 in Review
Parallel Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,893 shares — an estimated $76.2K sold.
Parallel Advisors first reported a position in APLS in Q2 2020 and held it in 24 quarters. The position peaked at $90.6K in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Parallel Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Parallel Advisors sold 1,893 Apellis Pharmaceuticals shares in Q2 2026, an estimated $76.2K.
- Parallel Advisors first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 24 quarters.
- Parallel Advisors's Apellis Pharmaceuticals position peaked at $90.6K in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.